Search bioRxiv⌕ Search

Biology subjects

Shavlakadze, T.

Publications and source records attributed to Shavlakadze, T..

5 recordsLinked to original sources

Quantitative imaging of native tissue architecture combined with deep multi-omics reveals the spatial biology of kidney aging

Aging alters tissue architecture and metabolism in spatially heterogeneous ways, yet the connections between these measurable structural and compositional phenotypes and underlying molecular changes are largely unknown. Here, we introduce NORIGAMI (NoRI-Guided AI for Multimodal Integration), a pipeline combining Normalized Raman Imaging (NoRI), deep learning, quantitative morphology, deep proteomics, and metabolomics to investigate renal aging. Unlike conventional histology, NoRI provides label-free, scattering-corrected measurements of absolute total protein and lipid mass concentrations (mg/mL). In 32 male rats aged 9, 18, 21 and 25 months, NORIGAMI predicted the chronological age of held-out rats from NoRI images (mean absolute error 0.78 months; R^2 = 0.97), and whole-tissue images outperformed models trained on isolated tubules. Quantitative imaging identified 41 age-associated morphological and compositional features (FDR < 0.05), revealing anatomically heterogeneous and non-linear changes in lipid droplet concentration, droplet size, cytoplasmic lipid concentration and tubular architecture. Deep molecular profiling quantified 11,485 proteins and 269 metabolites, revealing coordinated declines in differentiated proximal tubule (PT) identity and oxidative metabolism, selective increases in basement-membrane collagen-IV chains, and increasing molecular heterogeneity with age. A protein clock, built mainly from extracellular-matrix and heparan-sulfate proteins, predicted age with a mean absolute error of 1.6 months. Old kidneys diverged along a dominant injury-remodeling axis, seen separately in the proteome, in kidney RNA from 54 other rats and in the metabolome, in which tubular-injury and immune proteins, including the NAD+ consuming enzyme CD38, rise as differentiated-tubule proteins and NAD+ fall. NORIGAMI subsequently linked NAD+ associated molecular changes to quantitative features of tubular geometry and protein-lipid organization, while complementary KIM-1-centered analyses identified overlapping morphological associations involving epithelial injury and lipid handling and yielded additional molecular candidates for mechanistic validation. Collectively, these findings suggest that declining tubular metabolic function, altered lipid organization and injury-associated molecular programs represent interconnected features of renal aging. NORIGAMI establishes a framework for identifying the quantitative structural manifestations of molecular aging and generating spatially informed, experimentally testable hypotheses about tissue dysfunction.

physiology↗

Activin A correlates with the worst outcomes in COVID-19 patients, and can be induced by cytokines via the IKK/NF-kappa B pathway

A fraction of COVID-19 patients develop the most severe form, characterized by Acute Respiratory Disease Syndrome (ARDS). The molecular mechanisms causing COVID-19-induced ARDS have yet to be defined, though many studies have documented an increase in cytokines known as a "cytokine storm." Here, we demonstrate that cytokines that activate the NF-kappaB pathway can induce Activin A and its downstream marker, FLRG. In hospitalized COVID-19 patients elevated Activin A/FLRG at baseline were predictive of the most severe longitudinal outcomes of COVID-19, including the need for mechanical ventilation, lack of clinical improvement and all-cause mortality. Patients with Activin A/FLRG above the sample median were 2.6/2.9 times more likely to die, relative to patients with levels below the sample median, respectively. The study indicates high levels of Activin A and FLRG put patients at risk of ARDS, and blockade of Activin A may be beneficial in treating COVID-19 patients experiencing ARDS.

immunology↗

Age-related Gene Expression Signatures (AGES) in rats demonstrate early, late, and linear transcriptional changes from multiple tissues

In order to understand changes in gene expression that occur as a result of age, which might create a permissive or causal environment for age-related diseases, we produced a multi-timepoint Age-related Gene Expression Signature (AGES) from liver, kidney, skeletal muscle and hippocampus of rats, comparing 6, 9, 12, 18, 21, 24 and 27-month old animals. We focused on genes that changed in one direction throughout the lifespan of the animal, either early in life (early logistic changes); at mid-age (mid-logistic); late in life (late-logistic); or linearly, throughout the lifespan. The pathways perturbed as a result of chronological age demonstrate organ-specific and more global effects of aging, and point to mechanisms that might be counter-regulated pharmacologically in order to treat age-associated diseases. A small number of genes were regulated by aging in the same manner in every tissue, suggesting they may be more universal markers of aging.

systems biology↗

Inhibition of mTORC1 signaling in aged rats counteracts the decline in muscle mass and reverses multiple parameters of muscle signaling associated with sarcopenia

There is a lack of pharmacological interventions available for sarcopenia, a progressive age-associated loss of muscle mass, leading to a decline in mobility and quality of life. We found mTORC1 (mammalian target of rapamycin complex 1), a well-established critical positive modulator of mass, to be hyperactivated in sarcopenic muscle. Furthermore, inhibition of the mTORC1 pathway counteracted sarcopenia as determined by observing an increase in muscle mass and fiber type cross sectional area, surprising because mTORC1 signaling has been shown to be required for muscle mass gains in some settings. Additionally, several genes related to senescence were downregulated, while gene expression indicators of neuromuscular junction denervation were diminished using a low dose of a rapalog. Therefore mTORC1 inhibition may delay the progression of sarcopenia by directly and indirectly modulating multiple age-associated pathways, implicating mTORC1 as a therapeutic target to treat sarcopenia.

physiology↗

TORC1 inhibition as an immunotherapy to reduce infections in the elderly

mTOR inhibition extends lifespan and ameliorates aging-related pathologies including declining immune function in model organisms. The objective of this Phase 2a clinical trial was to determine if low dose mTOR inhibitor therapy enhanced immune function and thereby decreased infection rates in elderly subjects. The results indicate that 6 weeks of treatment with a low dose combination of a catalytic (BEZ235) plus an allosteric (RAD001) mTOR inhibitor (that selectively inhibits TORC1 downstream of mTOR) was safe, significantly decreased the rate of infections reported by elderly subjects for a year following study drug initiation, upregulated antiviral gene expression, and significantly improved influenza vaccination response. Thus selective TORC1 inhibition with a combination of BEZ235 and RAD001 may be efficacious as immunotherapy to reduce infections, a leading cause of death in the elderly.\n\nOne Sentence SummaryTreatment of elderly subjects with a low dose mTOR inhibitor regimen that selectively inhibits TORC1 significantly decreased infection rates

clinical trials↗